These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28350808)

  • 1. Differential recruitment efficacy of patient-derived amyloidogenic and myeloma light chain proteins by synthetic fibrils-A metric for predicting amyloid propensity.
    Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia LM; Lands RH; Kennel SJ; Wall JS
    PLoS One; 2017; 12(3):e0174152. PubMed ID: 28350808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A functional assay to identify amyloidogenic light chains.
    Martin EB; Williams AD; Heidel RE; Foster JS; Lands RH; Kennel SJ; Wall JS
    Amyloid; 2018 Jun; 25(2):93-100. PubMed ID: 29571269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis.
    Poshusta TL; Sikkink LA; Leung N; Clark RJ; Dispenzieri A; Ramirez-Alvarado M
    PLoS One; 2009; 4(4):e5169. PubMed ID: 19365555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin light chain amyloid aggregation.
    Blancas-Mejia LM; Misra P; Dick CJ; Cooper SA; Redhage KR; Bergman MR; Jordan TL; Maar K; Ramirez-Alvarado M
    Chem Commun (Camb); 2018 Sep; 54(76):10664-10674. PubMed ID: 30087961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity.
    Oberti L; Rognoni P; Barbiroli A; Lavatelli F; Russo R; Maritan M; Palladini G; Bolognesi M; Merlini G; Ricagno S
    Sci Rep; 2017 Dec; 7(1):16809. PubMed ID: 29196671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.
    Andrich K; Hegenbart U; Kimmich C; Kedia N; Bergen HR; Schönland S; Wanker E; Bieschke J
    J Biol Chem; 2017 Feb; 292(6):2328-2344. PubMed ID: 28031465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation.
    Mazzini G; Ricagno S; Caminito S; Rognoni P; Milani P; Nuvolone M; Basset M; Foli A; Russo R; Merlini G; Palladini G; Lavatelli F
    FEBS J; 2022 Jan; 289(2):494-506. PubMed ID: 34482629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains.
    Morgan GJ; Kelly JW
    J Mol Biol; 2016 Oct; 428(21):4280-4297. PubMed ID: 27569045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells.
    Keeling J; Teng J; Herrera GA
    Lab Invest; 2004 Oct; 84(10):1322-38. PubMed ID: 15286662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: A proof of concept.
    Ramirez-Alvarado M; Barnidge DR; Murray DL; Dispenzieri A; Marin-Argany M; Dick CJ; Cooper SA; Nasr SH; Ward CJ; Dasari S; Jiménez-Zepeda VH; Leung N
    Am J Hematol; 2017 Jun; 92(6):536-541. PubMed ID: 28295502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A constant domain mutation in a patient-derived antibody light chain reveals principles of AL amyloidosis.
    Rottenaicher GJ; Absmeier RM; Meier L; Zacharias M; Buchner J
    Commun Biol; 2023 Feb; 6(1):209. PubMed ID: 36823438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lysine modification on the stability and cellular binding of human amyloidogenic light chains.
    Davern S; Murphy CL; O'Neill H; Wall JS; Weiss DT; Solomon A
    Biochim Biophys Acta; 2011 Jan; 1812(1):32-40. PubMed ID: 20692337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
    Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
    Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Domain Interactions Determine the Amyloidogenicity of Antibody Light Chain Mutants.
    Weber B; Hora M; Kazman P; Pradhan T; Rührnößl F; Reif B; Buchner J
    J Mol Biol; 2020 Nov; 432(23):6187-6199. PubMed ID: 33058870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.
    Ami D; Lavatelli F; Rognoni P; Palladini G; Raimondi S; Giorgetti S; Monti L; Doglia SM; Natalello A; Merlini G
    Sci Rep; 2016 Jul; 6():29096. PubMed ID: 27373200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.
    Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V
    J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain.
    Klimtchuk ES; Gursky O; Patel RS; Laporte KL; Connors LH; Skinner M; Seldin DC
    Biochemistry; 2010 Nov; 49(45):9848-57. PubMed ID: 20936823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.
    Ward JE; Ren R; Toraldo G; Soohoo P; Guan J; O'Hara C; Jasuja R; Trinkaus-Randall V; Liao R; Connors LH; Seldin DC
    Blood; 2011 Dec; 118(25):6610-7. PubMed ID: 21998211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and biochemical characterization of plasma monoclonal free light chains in amyloidosis and multiple myeloma: a pilot study of intact and truncated forms of light chains and their charge properties.
    Kaplan B; Ramirez-Alvarado M; Dispenzieri A; Zeldenrust SR; Leung N; Livneh A; Gallo G
    Clin Chem Lab Med; 2008; 46(3):335-41. PubMed ID: 18254719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.